Metastatic mesenchymal chondrosarcoma showing a sustained response to cabozantinib: A case report

Metastatic mesenchymal chondrosarcoma showing a sustained response to cabozantinib: A case report

Mesenchymal chondrosarcoma is a rare and aggressive sarcoma subtype with high risk for distant metastases and poor prognosis. Currently NCCN- and ESMO-Guidelines recommend using Ewing sarcoma protocols as standard treatment. Nevertheless, in localized disease overall 5-year survival rates are below...

Full description

Bibliographic Details
Main Authors: Veronika Blum, Vanghelita Andrei, Baptiste Ameline, Silvia Hofer, Bruno Fuchs, Klaus Strobel, Anna Allemann, Beata Bode, Daniel Baumhoer
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Oncology
Subjects:
mesenchymal chondrosarcoma
metastatic disease
p16 loss
tyrosine kinase inhibitors
case report
cabozantinib
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1086677/full

Similar Items

Similar Items